Research On The Relationship Between R&D Investment And Performance Of Biomedical Enterprises

Entering the new era,the state has repeatedly emphasized the importance of innovation.R&D investment can provide the necessary financial support for enterprise innovation activities.With the increasingly fierce market competition,research and development activities play a more obvious role in enterprise performance,so it has attracted wide attention.Due to industry differences and national policy need not,the effect of R&D investment on enterprise performance is also different,biological pharmaceutical industry is the emerging industry,its development is closely related to people's physical and mental health,has the important status in the market,its research and development of production has obvious characteristics,R&D investment is the important guarantee that R&D activity,so the study of R&D investment in the industry and enterprise performance relationship is of great significance.On the basis of summarizing the related literature at home and abroad,the relevant hypothesis is put forward.Based on industry classification of shenyin wanguo,choose biological medicine in Shanghai and shen zhen a-share market listed companies as the research object,with the aid of spss23.0 software,using descriptive statistical analysis,Pearson correlation analysis combined with empirical research methods,such as multiple linear regression analysis,to the biological medicine enterprise R&D investment and enterprise performance,and R&D input lag affects corporate performance;Then enhua pharmaceutical company was selected for case study.The data from 2013 to 2018 were used as samples,and the above empirical analysis results were supplemented by trend analysis,correlation coefficient and fitting graph analysis,and relevant Suggestions were put forward according to the actual situation.The results show that the R&D investment intensity and R&D personnel investment intensity of biomedical enterprises are positively correlated with the corporate performance,and the R&D investment intensity has a lag on the corporate performance,which is obvious in the case of three lag periods,but not obvious in the case of R&D personnel investment intensity.There are obvious differences in R&D investment within the industry,and there is a certain gap between domestic enterprises and developed countries in Europe and the United States.Therefore,biomedical enterprises should establish long-term strategic goals,attach importance to R&D investment,improve their core competitiveness,and strive to make China a world-class biomedical power.